NCT05097586 RCT of At-Home tDCS for Depression in Pregnancy
| NCT ID | NCT05097586 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Women's College Hospital |
| Condition | Major Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 156 participants |
| Start Date | 2021-11-08 |
| Primary Completion | 2026-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 156 participants in total. It began in 2021-11-08 with a primary completion date of 2026-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized, sham-controlled trial to determine whether treatment with transcranial direct current stimulation (tDCS) is superior to a sham condition at reducing the symptoms of depression in pregnant people with moderate to severe depression. The study aims to enrol 156 participants across all sites. Data collection occurs at baseline, immediately after treatment, every 4 weeks during pregnancy and 4-, 12-, 26- and 52-weeks postpartum
Eligibility Criteria
Inclusion criteria: 1. Adult, ≥18 years of age 2. Singleton pregnancy, 12 to end of 32 weeks single gestation at randomization 3. In a major depressive episode (MDE) with at least moderate symptom severity (PHQ-9 ≥10 and confirmed using MINI International Neuropsychiatric Interview as MDE without psychotic features) 4. Assessed by a psychiatrist at one of the study recruitment sites during pregnancy, and offered the option of antidepressant medication for treatment but declined to use 5. No new treatments for depression (i.e. psychological or somatic) and no pharmacological treatment for depression in the 4 weeks prior to starting treatment Exclusion criteria: 1. Active alcohol or substance use disorder in previous 12 months as assessed by GAIN-SS 2. Active suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) 3. Bipolar disorder as assessed by MINI International Neuropsychiatric Interview 4. Schizophrenia or other psychotic disorder as assessed by MINI International Neuropsychiatric Interview 5. Major unstable or life-threatening medical illness (e.g. such as advanced cancer), pre-eclampsia/eclampsia in current pregnancy or neurologic illness or seizure history 6. Major congenital anomalies or major obstetrical complications in current pregnancy (determined by clinical PI/Co-I assessment) 7. Metal implants in cranium or any electrical implants 8. Benzodiazepine (except intermittent low-dose lorazepam no more than 2mg equivalent per day) or anticonvulsant use as these interfere with anodal tDCS 9. Visibly non-intact skin/rash on scalp areas at stimulation electrode sites 10. Unable to consent or complete study measures in English, or unable to complete depression in pregnancy workbook (the attention-control) in French or English
Contact & Investigator
Sophie Grigoriadis, MD, PhD
PRINCIPAL INVESTIGATOR
Sunnybrook Health Sciences Centre
Frequently Asked Questions
Who can join the NCT05097586 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Major Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05097586 currently recruiting?
Yes, NCT05097586 is actively recruiting participants. Contact the research team at simone.vigod@wchospital.ca for enrollment information.
Where is the NCT05097586 trial being conducted?
This trial is being conducted at Toronto, Canada, Toronto, Canada.
Who is sponsoring the NCT05097586 clinical trial?
NCT05097586 is sponsored by Women's College Hospital. The principal investigator is Sophie Grigoriadis, MD, PhD at Sunnybrook Health Sciences Centre. The trial plans to enroll 156 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.